Terbutaline Pump for the Prevention of Preterm Birth - Research Review - Final | AHRQ Effective Health Care Program

Uncertainty Surrounds Use of Terbutaline to Prevent Preterm Birth
A new AHRQ Effective Health Care Program research report concludes that not enough evidence is available to determine whether terbutaline administered by a subcutaneous infusion pump is both effective and safe in preventing repeat episodes of preterm labor. The report, Terbutaline Pump for the Prevention of Preterm Birth, found that the adverse effects of terbutaline pump therapy for mothers or their children, in both the short term and long term, are not fully understood. AHRQ’s new review found that the safety of the terbutaline pump is unclear, although post-marketing surveillance detected serious harms.  Some evidence suggests that pump therapy is beneficial for maintenance tocolysis. However, the studies have a high risk of bias and are insufficient in size to produce statistically significant results.
open here please:
Terbutaline Pump for the Prevention of Preterm Birth - Research Review - Final AHRQ Effective Health Care Program